Inovio Pharmaceuticals Inc. (NYSEMKT:INO)announced it has initiated a Phase 1/2a clinical trial to evaluate safety, immunogenicity and clinical responses of its immunotherapy product, INO-3112, in treating human papillomavirus (HPV)-associated head and neck cancer. INO-3112 is a combination of Inovio’s lead active immunotherapy product, VGX-3100, and its proprietary immune activator expressing interleukin-12 (IL-12). Inovio Pharmaceuticals Inc (NYSEMKT:INO) and weekly performance is 2.41%. On last trading day company shares ended up $9.34. Inovio Pharmaceuticals Inc (NYSEMKT:INO) distance from 50-day simple moving average (SMA50) is -7.30%.
Synthetic Biologics Inc (NYSEMKT:SYN) and Enterome Bioscience SA on June 10, 2014 announced that the two companies have entered into an agreement for conducting metagenomic research particularly on the effects of beta-lactam antibiotics. As part of the agreement, the two companies will study the effects of the aforementioned antibiotics on gastrointestinal microflora (microbiome) among the humans. Synthetic Biologics Inc (NYSEMKT:SYN) shares fell -9.15% in last trading session and ended the day on $1.49 . Its return on assets is -122.50 %. Synthetic Biologics Inc (NYSEMKT:SYN) quarterly performance is -46.40%.
On June 2, 2014, Relypsa, Inc. (NASDAQ:RLYP) a biopharmaceutical company, announced it has secured a loan facility of up to $35 million with Oxford Finance LLC (“Oxford”) and Silicon Valley Bank (“SVB”). Relypsa Inc (NASDAQ:RLYP) shares moved down -7.36% in last trading session and was closed at $22.91, while trading in range of $ 22.23 – 24.97.
June 2, 2014, Ohr Pharmaceutical, Inc. (NASDAQ:OHRP) a research and development company with a primary focus in ophthalmology, announced the closing of its previously announced acquisition of the assets of SKS Ocular LLC. In connection with this transaction, three of the cofounders of SKS Ocular are being appointed to senior management and advisory roles at Ohr. Jason Slakter, MD has been appointed Chief Medical Officer and is expected to join the Board of Directors.OHR Pharmaceutical Inc (NASDAQ:OHRP) ended the last trading day at $ 8.60. Company weekly volatility is calculated as 6.59% and price to cash ratio as 50.78. OHR Pharmaceutical Inc (NASDAQ:OHRP) showed a negative weekly performance of -1.26%.
On June 3, 2014, Hyperion Therapeutics, Inc. (NASDAQ:HPTX) announced that the validation period is complete for its New Drug Submission (NDS) to Health Canada for RAVICTI (glycerol phenylbutyrate) Oral Liquid for the treatment of urea cycle disorders (UCDs), and that the RAVICTI NDS was granted Priority Review. Hyperion Therapeutics Inc (NASDAQ:HPTX) net profit margin is 44.20% and weekly performance is -9.75%. On last trading day company shares ended up $26.00. Analysts mean target price for the company is $39.20. Hyperion Therapeutics Inc (NASDAQ:HPTX) distance from 50-day simple moving average (SMA50) is 1.14%.
Leave a Reply